Colorectal Cancer

Molecular Staging of Colon Cancer

 

According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer in the United States, and the second leading cause of cancer related death. In 2011 alone, there was upwards of 140,000 new cases, and approximately 49,380 deaths that same year as a result of the disease.

Colorectal cancer is the third most commonly diagnosed cancer in the United States, and the second leading cause of cancer related death.

Maybe the most threatening aspect of colorectal cancer is the fact that virtually everyone is at risk of being diagnosed with it at some point in their life. The risk is evenly balanced between men and women – both of which have a 5% likelihood of being diagnosed. An individual’s odds of being diagnosed increases with age. Approximately 90% of new cases occur with individuals over the age of 50.

There is a 5% likelihood of being diagnosed.

Despite its seemingly unbiased nature, one of the key meters for measuring how at-risk an individual may be of contracting colorectal cancer is by examining their family’s history. If an immediate family member has been diagnosed in the past, an individual stands to be 2 to 3 times more likely to develop the disease.

Our bioprofiles for the disease have not only uncovered previously undiscovered biomarkers, but has also given us the sensitivity to differentiate the stage of colorectal cancer and precancerous lesions for a given patient.

At Paradise Genomics, we’ve analyzed clinically qualified tumor samples to obtain dynamic bioprofiles for the determination of progression of colorectal cancer. Our bioprofiles for the disease have not only uncovered previously undiscovered biomarkers, but has also given us the sensitivity to differentiate the stage of colorectal cancer and precancerous lesions for a given patient. We are currently working to collaborate with leading pharmaceutical and diagnostics companies to enable more effective diagnosis and therapeutics.

CC HeatMap

The Paradise Genomics Bioprofile for Malignant Colon Tumors